Jay David Caplan - 27 Feb 2025 Form 4 Insider Report for FRACTYL HEALTH, INC. (GUTS)

Reporting relationship: President, Chief Product Off.
Issuer ticker: GUTS
Reported as of: 27 Feb 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Mar 2025, 20:59:55 UTC
Prior SEC filing: 03 Feb 2025
Next SEC filing: 17 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Lisa A. Davidson, Attorney-in-fact

Key filing fact

Jay David Caplan filed Form 4 for FRACTYL HEALTH, INC. (GUTS) on 03 Mar 2025.

Key facts

This page summarizes Jay David Caplan's Form 4 filing for FRACTYL HEALTH, INC. (GUTS).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 03 Mar 2025, 20:59.

Change

Previous filing in this sequence was filed on 03 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GUTS transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +179,700
Change %
Price: $0.000000
Shares after: 179,700
Date: 27 Feb 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 179,700
Exercise price: $1.46
Footnotes: F1

GUTS transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +104,400
Change %
Price: $0.000000
Shares after: 104,400
Date: 27 Feb 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 104,400
Exercise price: $15.00
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The stock option vests and becomes exercisable in equal installments on each of the first four anniversaries of the grant date, subject to the Reporting Persons's continuing in employment through each such vesting date.

Footnote F2

In connection with the Issuer's initial public offering, on February 1, 2024 the Reporting Person was granted, subject to the satisfaction of certain performance criteria, an option to purchase 174,000 shares of common stock to vest in the form of shares of the Issuer's common stock in four substantially equal installments on December 31, 2024 and each of the first three anniversaries thereof. On February 27, 2025, the Issuer's administrator determined that the performance criteria were partially met, resulting in 104,400 shares subject to such option being earned, of which 25% vested on December 31, 2024 and the remaining 75% will vest in substantially equal installments on the first three anniversaries thereof.